1. Inhibition of amyloid fibrillation of lysozyme by phenolic compounds involves quinoprotein formation.
- Author
-
Feng S, Song XH, and Zeng CM
- Subjects
- Amyloid antagonists & inhibitors, Amyloid ultrastructure, Benzoquinones chemistry, Benzoquinones metabolism, Benzoquinones pharmacology, Catechols chemistry, Catechols metabolism, Catechols pharmacology, Dose-Response Relationship, Drug, Electrophoresis, Polyacrylamide Gel, Hydroquinones chemistry, Hydroquinones metabolism, Hydroquinones pharmacology, Kinetics, Microscopy, Electron, Transmission, Molecular Structure, Muramidase antagonists & inhibitors, Muramidase ultrastructure, Phenols chemistry, Phenols pharmacology, Protein Binding, Resorcinols chemistry, Resorcinols metabolism, Resorcinols pharmacology, Amyloid metabolism, Muramidase metabolism, Phenols metabolism
- Abstract
Numerous phenolic compounds have been reported to have an inhibitory role on amyloid formation of proteins. The present study, utilizing lysozyme as a model system, examined the anti-amyloidogenic effects of phenol and three diphenol epimers. The results indicated that catechol and hydroquinone dose-dependently inhibited lysozyme fibrillation and covalently bound to the peptide chains to form quinoproteins, showing a similar effect to benzoquinone. In contrast, phenol and resorcinol did not modify the peptide with a quinone moiety, showing no effect on lysozyme fibrillation. We suggest that quinone intermediates are the active form for a phenolic compound to inhibit lysozyme fibrillation. The modification of lysozyme with quinone moieties alters the interacting forces between peptide chains and consequently interrupts the process of lysozyme fibrillation., (Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF